Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
Paul C, Coustou D, Lahfa M, Bulai-Livideanu C, Doss N, Mokthar I, Turki H, Nouira R, Fazaa B, Ben Osman A, Zourabichvili O, Cazeau C, Coubetergues H, Picot S, Bienvenu AL, Voisard JJ. Paul C, et al. Among authors: doss n. Dermatology. 2013;227(2):157-64. doi: 10.1159/000353667. Dermatology. 2013. PMID: 24051622 Clinical Trial.
[Fluconazole and treatment of onychomycosis. About 86 cases].
El Euch D, Bouassida S, Kourda M, Ezzine N, Denguezli M, Mokhtar I, Doss N, Turki H, Ridha Kamoun M, Nouira R, Ben Osman Dhahril A. El Euch D, et al. Among authors: doss n. Tunis Med. 2006 Oct;84(10):640-3. Tunis Med. 2006. PMID: 17193857 Clinical Trial. French.
Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.
Doss N, Kamoun MR, Dubertret L, Cambazard F, Remitz A, Lahfa M, de Prost Y. Doss N, et al. Pediatr Allergy Immunol. 2010 Mar;21(2 Pt 1):321-9. doi: 10.1111/j.1399-3038.2009.00895.x. Epub 2009 Jun 26. Pediatr Allergy Immunol. 2010. PMID: 19563466 Clinical Trial.
Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study.
Mokni M, Dupuy A, Denguezli M, Dhaoui R, Bouassida S, Amri M, Fenniche S, Zeglaoui F, Doss N, Nouira R, Ben Osman-Dhahri A, Zili J, Mokhtar I, Kamoun MR, Zahaf A, Chosidow O. Mokni M, et al. Among authors: doss n. Dermatology. 2006;212(2):108-12. doi: 10.1159/000090649. Dermatology. 2006. PMID: 16484815
EPIMAG: International Cross-Sectional Epidemiological Psoriasis Study in the Maghreb.
Ammar-Khodja A, Benkaidali I, Bouadjar B, Serradj A, Titi A, Benchikhi H, Amal S, Hassam B, Sekkat A, Mernissi FZ, Mokhtar I, Dahoui R, Denguezli M, Doss N, Turki H. Ammar-Khodja A, et al. Among authors: doss n. Dermatology. 2015;231(2):134-44. doi: 10.1159/000382123. Epub 2015 Jun 19. Dermatology. 2015. PMID: 26111474
[Familial psoriasis: descriptive report of 9 families].
Ammar M, Zaraa I, Bouchleka Souissi C, Dhaoui A, Doss N, Ben Osman A, El Gaied A, Mokni M. Ammar M, et al. Among authors: doss n. Tunis Med. 2009 Nov;87(11):750-4. Tunis Med. 2009. PMID: 20209833 Free article. French.
100 results